Understanding the difference between HCG monotherapy, testosterone-only therapy
Severe low testosterone symptoms may necessitate starting with TRT, while significant weight loss goals might prioritize a GLP-1 like semaglutide. One of the biggest concerns when starting two medications at the same time is that if a side effect occurs, it can be difficult to know which one caused it, says Staheli
From there each plan is designed from your data, whether that is cagrilintide alone, cagrilintide combined with a GLP-1 medication, or a broader plan that adds hormone optimization and nutritional support
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
In short: in the lab, BPC157 often looks benign
The 28-day shelf life reflects both peptide stability and microbial protection concerns
